News & Updates
Filter by Specialty:
Gemcitabine for IR-NMIBC tied to more recurrence vs BCG
Treatment-naive patients with immediate-risk (IR) nonmuscle-invasive bladder cancer (NMIBC) who received gemcitabine appear to have greater recurrence risk than those given Bacillus Calmette-Guerin (BCG). Both treatments, however, are effective against disease progression.
Gemcitabine for IR-NMIBC tied to more recurrence vs BCG
06 Jun 2025
VIDEO: Apalutamide’s tolerability in prostate cancer patients
Dr Darren Poon, Specialist in Clinical Oncology at Hong Kong Sanatorium & Hospital and Honorary Clinical Associate Professor at the Chinese University of Hong Kong, discusses apalutamide’s tolerability in prostate cancer patients.
VIDEO: Apalutamide’s tolerability in prostate cancer patients
19 May 2025
Nerve-sparing technique preserves erectile function after RARP
A nerve-sparing technique decreases erectile dysfunction in men undergoing robot-assisted radical prostatectomy (RARP) for prostate cancer in a phase III study.
Nerve-sparing technique preserves erectile function after RARP
13 May 2025
Rectal spacer relieves GI issues following RT for prostate cancer
In a large retrospective study, the incidence of bowel disorders and related procedures dropped when a polyethylene glycol-based hydrogel spacer (PHS) was used in men undergoing radiotherapy (RT) for prostate cancer.
